Sector News

Smith & Nephew shares jump 10pc on Stryker bid reports

December 26, 2014
Life sciences
Shares in Smith & Nephew spiked by almost 10pc on Wednesday following reports that its US rival Stryker is planning a £13bn takeover bid.
 
Stryker, which makes surgical implants, is looking at offering a 30pc premium to Smith & Nephew’s share price, which rose to £11.80 on Wednesday morning, valuing the company at around £10.6bn. THe stock closed up 7.7pc at £11.73 on Wednesday.
 
An approach could be made within weeks, Bloomberg reported.
 
In May, Stryker boss Kevin Lobo admitted that he was in the early stages of considering an acquisition of Smith & Nephew but was not prepared to make an immediate bid. The statement put Stryker in a “cooling-off” period that prevented it from approaching the FTSE 100 company until November.
 
Stryker has held discussions on financing the deal, and already considered the competition issues of a tie-up, according to Bloomberg citing unnamed sources.
 
The UK’s takeover rules state that when a potential bidder is in a cool-off period it can still actively consider an offer but it is banned from “taking any steps in connection with a possible offer for the [target] company where knowledge of the possible offer might be extended outside those who need to know in the potential offeror and its immediate advisers”. As a result, it is widely accepted that talks must be kept to only dedicated advisers in order to keep leaks to a minimum.
 
The Michigan-based company is reportedly not weighing a so-called inversion deal – an acquisition which involves a US company moving its headquarters outside the country to escape high corporation tax rates at home.
 
While inversions surged in popularity in the early part of this year, a US Treasury clampdown in September scuppered a number of high profile deals, including AbbVie’s abandoned tie-up with Shire, and stopped other potential deals in their tracks.
 
Analysts are divided over the strategic logic of a Stryker and Smith & Nephew tie-up. Morgan Stanley analysts noted that a merger would slow the US company’s annual growth, which currently stands at around 5pc compared with Smith & Nephew’s 3pc.
 
Analysts at Bernstein have, however, put the chances of a merger at more than a third, saying a tie-up could help cut costs at a time when the industry is facing intense pricing pressure. They also said Stryker could be keen for a merger to help it compete with the scale of the combined Zimmer and Biomet, two major US medical technology companies who announced plans to merge earlier this year.
 
By Andrew Trotman, Denise Roland and Ashley Armstrong
 

comments closed

Related News

October 17, 2021

Colorcon acquires a majority share in Ideal Cures Pvt. Ltd., India

Life sciences

Ideal Cures will operate as a fully independent entity within Colorcon. Their business complements Colorcon’s position in the Indian pharmaceutical market with a strong presence in the domestic generic sector comprised of long-standing customer relationships sustained by innovative and customized solutions.

October 17, 2021

Barriers exist, but participation urgent in breast cancer clinical trials: report

Life sciences

Across four new breast cancer treatments approved by the FDA last year, 2% to 9% of patients in clinical trials for the drugs were Black Americans and 0% to 9% were Hispanic, according to a new report from Breastcancer.org.

October 17, 2021

Danish consortium acquires part of Jernbanebyen to create one of the world’s healthiest urban villages

Life sciences

The southern section of Jernbanebyen in central Copenhagen has a new owner. The Baneby Consortium, comprising NREP, Novo Holdings and Industriens Pension, has bought the land from Freja Ejendomme. The ambition is to create a green, partly car-free environment that will also be one of the healthiest in the world. 

Send this to a friend